Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All adintrevimab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAdintrevimabAdintrevimab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19

Zumbrun et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.01353-22
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hamster and monkey study showing dose-dependent protection against SARS-CoV-2 infection with prophylactic administration of a single dose of adintrevimab.
Zumbrun et al., 24 Jan 2023, USA, peer-reviewed, 17 authors. Contact: knarayan@invivyd.com.
This PaperAdintrevimabAll
Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
Elizabeth E Zumbrun, Chengzi I Kaku, Lukas Dillinger, Samantha E Zak, Ana I Kuehne, Russel R Bakken, Jeffrey W Koehler, Korey L Delp, Christopher P Stefan, Raina Kumar, Jeffrey R Kugelman, Alicia M Moreau, Xiankun Zeng, John M Dye, Andrew S Herbert, Kristin Narayan, Laura M Walker
Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.01353-22
Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prophylactic administration of a single dose of adintrevimab provided protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner, as measured by significant reductions in lung viral load and virus-induced lung pathology, and by inhibition of viral replication in the upper and lower respiratory tract.
References
Andrews, Stowe, Kirsebom, Toffa, Rickeard et al., COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant, N Engl J Med, doi:10.1056/NEJMoa2119451
Dejnirattisai, Huo, Zhou, Zahradník, Supasa et al., SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, doi:10.1016/j.cell.2021.12.046
Dejnirattisai, Zhou, Supasa, Liu, Mentzer et al., Antibody evasion by the P.1 strain of SARS-CoV-2, Cell, doi:10.1016/j.cell.2021.03.055
Imai, Iwatsuki-Horimoto, Hatta, Loeber, Halfmann et al., Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2009799117
Kaku, Narayan, Schmidt, Engler, Li et al., ADG20, a half-life-extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants
Liu, Ginn, Dejnirattisai, Supasa, Wang et al., Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum, Cell, doi:10.1016/j.cell.2021.06.020
Liu, Iketani, Guo, Chan, Wang et al., Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2, Nature, doi:10.1038/s41586-021-04388-0
Martinez, Schäfer, Gobeil, Li, De La Cruz et al., A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice, Sci Transl Med, doi:10.1126/scitranslmed.abj7125
Osterrieder, Bertzbach, Dietert, Abdelgawad, Vladimirova et al., Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters, Viruses, doi:10.3390/v12070779
Rappazzo, Tse, Kaku, Wrapp, Sakharkar et al., Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody, Science, doi:10.1126/science.abf4830
Rogers, Zhao, Huang, Beutler, Burns et al., Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model, Science, doi:10.1126/science.abc7520
Sia, Yan, Chin, Fung, Choy et al., Pathogenesis and transmission of SARS-CoV-2 in golden hamsters, Nature, doi:10.1038/s41586-020-2342-5
Vegivinti, Evanson, Lyons, Akosman, Barrett et al., Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials, BMC Infect Dis, doi:10.1186/s12879-022-07068-0
Who, Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update, WHO
{ 'indexed': {'date-parts': [[2023, 7, 25]], 'date-time': '2023-07-25T16:52:51Z', 'timestamp': 1690303971674}, 'reference-count': 15, 'publisher': 'American Society for Microbiology', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2023, 1, 24]], 'date-time': '2023-01-24T00:00:00Z', 'timestamp': 1674518400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://doi.org/10.1128/ASMCopyrightv2'}, { 'start': { 'date-parts': [[2023, 1, 24]], 'date-time': '2023-01-24T00:00:00Z', 'timestamp': 1674518400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://journals.asm.org/non-commercial-tdm-license'}], 'content-domain': {'domain': ['journals.asm.org'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 1, 24]]}, 'abstract': '<jats:p>Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have ' 'broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ' 'variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden ' 'hamster and rhesus macaque models, prophylactic administration of a single dose of ' 'adintrevimab provided protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent ' 'manner, as measured by significant reductions in lung viral load and virus-induced lung ' 'pathology, and by inhibition of viral replication in the upper and lower respiratory ' 'tract.</jats:p>', 'DOI': '10.1128/aac.01353-22', 'type': 'journal-article', 'created': { 'date-parts': [[2022, 12, 15]], 'date-time': '2022-12-15T14:02:42Z', 'timestamp': 1671112962000}, 'update-policy': 'http://dx.doi.org/10.1128/asmj-crossmark-policy-page', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 ' 'in Hamster and Non-Human Primate Models of COVID-19', 'prefix': '10.1128', 'volume': '67', 'author': [ { 'given': 'Elizabeth E.', 'family': 'Zumbrun', 'sequence': 'first', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Chengzi I.', 'family': 'Kaku', 'sequence': 'additional', 'affiliation': [{'name': 'Adimab LLC, Lebanon, New Hampshire, USA'}]}, { 'given': 'Lukas', 'family': 'Dillinger', 'sequence': 'additional', 'affiliation': [{'name': 'Invivyd, Inc., Waltham, Massachusetts, USA'}]}, { 'given': 'Samantha E.', 'family': 'Zak', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Ana I.', 'family': 'Kuehne', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Russel R.', 'family': 'Bakken', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Jeffrey W.', 'family': 'Koehler', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Korey L.', 'family': 'Delp', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Christopher P.', 'family': 'Stefan', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Raina', 'family': 'Kumar', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Jeffrey R.', 'family': 'Kugelman', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Alicia M.', 'family': 'Moreau', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Xiankun', 'family': 'Zeng', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'John M.', 'family': 'Dye', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'given': 'Andrew S.', 'family': 'Herbert', 'sequence': 'additional', 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, ' 'Frederick, Maryland, USA'}]}, { 'ORCID': 'http://orcid.org/0000-0002-7977-4783', 'authenticated-orcid': True, 'given': 'Kristin', 'family': 'Narayan', 'sequence': 'additional', 'affiliation': [{'name': 'Invivyd, Inc., Waltham, Massachusetts, USA'}]}, { 'given': 'Laura M.', 'family': 'Walker', 'sequence': 'additional', 'affiliation': [{'name': 'Invivyd, Inc., Waltham, Massachusetts, USA'}]}], 'member': '235', 'reference': [ { 'key': 'e_1_3_3_2_2', 'unstructured': 'WHO. 2022. Coronavirus disease (COVID-19) weekly epidemiological update ' 'and weekly operational update. WHO Geneva Switzerland. Available from ' 'https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.'}, {'key': 'e_1_3_3_3_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2119451'}, {'key': 'e_1_3_3_4_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-021-04388-0'}, {'key': 'e_1_3_3_5_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12879-022-07068-0'}, {'key': 'e_1_3_3_6_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2021.03.055'}, {'key': 'e_1_3_3_7_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2021.06.020'}, {'key': 'e_1_3_3_8_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abf4830'}, {'key': 'e_1_3_3_9_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2021.12.046'}, { 'key': 'e_1_3_3_10_2', 'volume-title': 'ADG20, a half-life-extended monoclonal antibody in development for the ' 'prevention and treatment of COVID-19, demonstrated broad in vitro ' 'neutralisation against SARS-CoV-2 variants.', 'author': 'Kaku CI', 'year': '2022', 'unstructured': 'Kaku CI, Narayan K, Schmidt P, Engler F, Li Y, Walker LM. 2022. ADG20, a ' 'half-life-extended monoclonal antibody in development for the prevention ' 'and treatment of COVID-19, demonstrated broad in vitro neutralisation ' 'against SARS-CoV-2 variants. Abstract. European Congress of Clinical ' 'Microbiology & Infectious Diseases (ECCMID), Lisbon, Portugal.'}, { 'key': 'e_1_3_3_11_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/scitranslmed.abj7125'}, { 'key': 'e_1_3_3_12_2', 'volume-title': 'Guide for the care and use of laboratory animals', 'author': 'National Research Council (US) Committee for the Update of the Guide for the ' 'Care and Use of Laboratory Animals', 'year': '2011', 'unstructured': 'National Research Council (US) Committee for the Update of the Guide for ' 'the Care and Use of Laboratory Animals. 2011. Guide for the care and use ' 'of laboratory animals, 8th ed. National Academies Press, Washington, DC. ' 'Available from https://www.ncbi.nlm.nih.gov/books/NBK54050/.', 'edition': '8'}, {'key': 'e_1_3_3_13_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.2009799117'}, {'key': 'e_1_3_3_14_2', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v12070779'}, {'key': 'e_1_3_3_15_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2342-5'}, {'key': 'e_1_3_3_16_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abc7520'}], 'container-title': 'Antimicrobial Agents and Chemotherapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.asm.org/doi/pdf/10.1128/aac.01353-22', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://journals.asm.org/doi/pdf/10.1128/aac.01353-22', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 1, 24]], 'date-time': '2023-01-24T14:05:22Z', 'timestamp': 1674569122000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.asm.org/doi/10.1128/aac.01353-22'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 1, 24]]}, 'references-count': 15, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2023, 1, 24]]}}, 'alternative-id': ['10.1128/aac.01353-22'], 'URL': 'http://dx.doi.org/10.1128/aac.01353-22', 'relation': {}, 'ISSN': ['0066-4804', '1098-6596'], 'subject': ['Infectious Diseases', 'Pharmacology (medical)', 'Pharmacology'], 'container-title-short': 'Antimicrob Agents Chemother', 'published': {'date-parts': [[2023, 1, 24]]}, 'assertion': [ { 'value': '2022-10-07', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-11-30', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-12-15', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit